The advent of anti-neovascular therapies in cancer and eye disease has prompted a burgeoning interest in the mechanisms behind the initiation, development and refinement of new vessel formation. The growth of new vessels from those already established is termed angiogenesis and although a complex process, involving over 50 growth factors, cytokines, receptors and enzymes, is dominated, in most situations, by the 38 kDa cysteine-knot protein vascular endothelial growth factor (VEGF). Following the initial identification of VEGF (Senger et al, 1983) many splice isoforms were subsequently identified, eventually forming a family of mature peptides -the VEGF xxx family (see Figure 1) (Houck et al, 1991) . The individual family members have different expression patterns (e.g., VEGF 183 expression is mostly restricted to the eye (Jingjing et al, 1999) , VEGF 145 in the reproductive system (Charnock-Jones et al, 1993) ); unique characteristics with respect to heparin and receptor-binding properties (resulting from inclusion/exclusion of particular exon segments) and are named by amino acid size. Despite this heterogeneity they are all considered pro-angiogenic, pro-permeability vasodilators. The evidence for these properties for individual splice isoform recombinant proteins in vivo, however, varies from conclusive (VEGF 165 ) (Leung et al, 1989) , through mixed (VEGF 121 ) (Keyt et al, 1996; Zhang et al, 2000) and scanty (VEGF 145 ) (Poltorak et al, 1997) to absent (VEGF 206 ).
In addition, it has now become evident that even the presence of six splice isoforms is an over-simplification. The pro-angiogenic potential of conventional VEGF isoforms is thought to result from the C-terminus (Keyt et al, 1996) , more specifically the six amino acids of exon 8a -CDKPRR (Cebe Suarez et al, 2006; Cebe-Suarez et al, 2008) . A sister family of splice isoforms has now been identified (see Figure 1 ) in which the pro-angiogenic domain (exon 8a) is replaced by the six amino acids coded for by exon 8b -SLTRKD. These exon 8b isoforms (VEGF xxx b) are exemplified by the only isoform so far extensively investigated, VEGF 165 b. VEGF 165 b has radically different properties to that of the widely studied VEGF 165 . We, and others have shown that VEGF 165 b is not pro-angiogenic in vivo (Woolard et al, 2004) and specifically and actively inhibits VEGF 165 -mediated endothelial cell proliferation and migration in vitro (Bates et al, 2002; Rennel et al, 2008a, b) , vasodilatation ex vivo (Bates et al, 2002) and in vivo angiogenesis assays such as rabbit corneal eye pocket, chicken chorioallantoic membrane, mesenteric and Matrigel implants (Woolard et al, 2004; Cebe Suarez et al, 2006; Kawamura et al, 2008) . Furthermore, VEGF 165 b not only inhibits physiological angiogenesis in developing mammary tissue in transgenic animals over-expressing VEGF 165 b but also pathological angiogenesis in models of the proliferative ocular lesions of diabetes (retinopathy of pre-maturity) (Konopatskaya et al, 2006) and age-related macular degeneration (laser-induced choroidal neovascularisation, Hua et al, unpublished) and in six different tumour models in vivo (Woolard et al, 2004; Varey et al, 2008; Rennel et al, 2008a, b) . The above anti-angiogenic properties occur when delivered as VEGF 165 b-transfected cells (Woolard et al, 2004; Varey et al, 2008; Rennel et al, 2008a) , VEGF 165 b-adenoviral constructs (Woolard et al, 2004) or recombinant human protein (Konopatskaya et al, 2006; Rennel et al, 2008b) .
Although a significant amount of evidence on the expression and function of the VEGF 165 b isoform has already been published, there is very little evidence on other VEGF xxx b family members, and their existence and activity is still uncertain. This study, therefore, investigates the properties of a second member of the VEGF xxx b family -the peptide VEGF 121 b, addressing the hypothesis that VEGF 121 b will also show anti-angiogenic properties. We present descriptive expression data and functional data on cell migration, receptor binding and in vivo tumour and ocular angiogenesis in vivo.
MATERIALS AND METHODS

Tissue samples
Paired colon samples were from partial colon resection for carcinoma. Samples were obtained by taking biopsies of the fresh specimen from a non-necrotic central portion of the tumour and from a peripheral part of the macroscopically normal colon (n ¼ 15). The mean patient age was 71.5 (58 -80) years, with 62% males and Duke's staging as follows: 6.7% A, 46.7% B and 46.7% C. Informed consent for obtaining the tissue was gained in compliance with local ethics committee approval.
PCR on cDNA from human total RNA Total RNA was extracted from human tissue using TRIZOL (Invitrogen, Carlsbad, CA, USA) (Chomczynski, 1993) and treated with DNase (Promega, Madison, WI, USA). Complementary DNA was made using oligo dT primers or 3 0 UTR primer (GCTCTA GAAGCAGGTGAGAGTAAGCG) as described earlier (Bates et al, 2002 Figure 1 Alternative splicing of VEGF-A generating VEGF xxx and VEGF xxx b isoforms. (A) VEGF-A contains eight exons with receptor binding found in exons 3 and 4, heparin and neuropilin binding in exons 6 and 7 and 8a. (B) Alternative splicing of the C-terminal end using proximal splice site generating VEGF xxx isoforms or distal splice site generating VEGF xxx b isoforms. This splicing leads to an alterative last six amino acids (CDKPRR or SLTRKD). (C) The C-terminal splicing leads to the possibility of two sister families of VEGF-A isoforms; VEGF xxx and VEGF xxx b, differing only in the C-terminal.
AAA, 3
0 UTR II CTGGATTAAGGACTGTTCTG, VEGF 121 exon 5/8a GAAAAATGTGACAAGCCGAG 3 0 UTR II CTGGATTAAGGACTGT TCTG, GAPDH forward TGATGACATCAAGAAGGTGGTGAAG, reverse TCCTTGGAGGCCATGTGGGCCAT and PCR products were separated and visualised using 4% agarose/ethidium bromide gel. Putative VEGF 121 b PCR products were purified using QIAquick gel extraction (Qiagen, Crawley, UK) and inserted into pGEM vector and confirmed by sequencing of plasmid.
Production of recombinant protein
Recombinant human VEGF 121 b (VEGF 121 b) and VEGF 165 b were produced in Chinese hamster ovary cells as glycosylated dimers by Cancer Research Technologies (London, UK) as described earlier (Rennel et al, 2008b) . VEGF 165 and VEGF 121 were from R&D Systems, Minneapolis, MN, USA.
In vitro assays with human umbilical vein endothelial cells
Human umbilical vein endothelial cells (HUVEC) were extracted from umbilical cords from caesarean sections (St Michael's Hospital, Bristol, UK). HUVEC migration was performed as described earlier (Rennel et al, 2008b) . Briefly, HUVECs were serum starved for 6 h and 100 000 serum-starved cells were plated into collagen-coated 8 mm inserts (Millipore, Billerica, MA, USA) placed in 24-well plates with 500 ml of chemoattractant in M200 medium with 0.1% v/v FCS and 0.2% w/v BSA and incubated overnight at 371C to allow for migration. Migrating cells were stained in Mayer's haematoxylin. Migrating cells were counted (10 random fields per insert) and expressed as percentage of migrating cells in relation to the total number of seeded cells. Experiments were performed in triplicates. A peptide (Ac-SLTRKD) was generated and increasing concentrations (1 nM -100 mM) peptide was combined with or without 1 nM VEGF 165 to analyse impact on HUVEC migration.
Cell cytotoxicity was performed using a lactate dehydrogenase assay (Promega); 13 000 cells were seeded in cell culture 96-well plates in triplicates or quadruplicates in 100 ml of full growth media (FGM) for 24 h. Recombinant VEGF protein was added in 100 ml media with 0.1% FCS for 48 h. Conditioned media and lysed cells were spun at 250 g for 15 min at 41C followed by addition of kit components, incubated for 30 min and read at 490 nm. Receptor and kinase inhibitors were added at indicated concentrations with or without 1.4 nM VEGF 121 b.
For direct counting, HUVECs were seeded in 24-well plates in triplicates in FGM 24 h followed by 48 h exposure to 1.4 nM growth factors or FGM. Cells were trypsinised and counted using a haemocytometer.
In vivo tumour model
LS174t human colon carcinoma cell lines (ECACC, Salisbury, UK) (Yuan et al, 1996; Lee et al, 2000) were grown in Minimum Essential Eagle's Medium supplemented with 10% v/v FCS, 2 mM L-glutamine and 1% non-essential amino acids (all from Sigma Aldrich, Gillingham, UK). Cells were transfected with 1 mg/well of pcDNA 3 empty vector or pcDNA 3 -VEGF 121 b, using lipofectamine plus (Invitrogen) as per manufacturer's instructions and selected using 500 mg ml À1 geneticin (Sigma Aldrich). Conditioned media and cell lysate were analysed by western blotting to confirm expression levels of VEGF isoforms. Two million cells were injected subcutaneously into the lumbar region of nude mice (six per group). Xenotransplanted tumours were measured by calliper every 2 -3 days and tumour volume was calculated according to (length Â width Â [length þ width]/2). Mice were culled by cervical dislocation and tumours were removed when the first tumour reached 16 mm in any direction all mice were killed in that group. Injections, measurements and analysis were all carried out with the investigators blinded to group.
Tumour vessel density was counted in 10 random fields in haematoxylin and eosin stained 6 mm sections frozen sections from tumours. Vessel presence was confirmed by staining by blocking in 5% v/v goat Ig for 30min, 20mg ml À1 biotinylated isolectin B4 (L-2140 Sigma-Aldrich) or 1 mg ml À1 Flk-1 (sc-6251, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight, 2 mg ml À1 anti-mouse biotin antibody (Vector Laboratories, Burlingame, CA, USA) for 1 h followed by avidin biotinylated enzyme complex (Vector Laboratories) for 30 min followed by DAB substrate (Vector Laboratories). Sections were examined using a Nikon Eclipse E400 microscope and photos were captured using Nikon Eclipse Net software. To visualise apoptosis, tumour sections were stained with cleaved caspase 3 antibody (1 : 400 dilution, CatNo9661 Cell Signaling Technology, Danvers, MA, USA) and positive staining areas were circled and compared to total tumour area using Image J software.
Cell proliferation by flow cytometry analysis and direct counting
Trypsinised LS174t cells were fixed in 70% ethanol for 30 min at 4 1C followed by 100 mg ml À1 ribonuclease (Sigma Aldrich) for 5 min. Propidium iodine (PI, 50 mg ml À1 ) was added to the cells and analysed by flow cytometer.
For healthy, apoptotic and necrotic cell determination a PI-annexin V-FITC kit was used (Bender MedSystems, Vienna, Austria). Cell culture media was centrifuged at 1500 r.p.m. to collect non-adherent cells, added to trypsined cells and diluted in binding buffer to approximately 300 000 cells/ml. Cells were stained with 25 ml annexin V-FITC for 10 min, washed, stained with 20 mg ml À1 PI and analysed by flow cytometer. For direct counting, 135 000 LS174t cells/24 well was seeded out in triplicates in media supplemented with 0.1% FCS in the presence or absence of 1 nM VEGF 121 b. Cells were trypsined and counted using a haemocytometer after 24 and 48 h. 
SDS -PAGE and immunoblotting of tissue and cell lysate
Tissue lysates from transfected cells or human colon tissue were extracted using RIPA buffer (50 mM Tris, 150 mM NaCl, 1% v/v NP-40, 0.25% w/v Na-deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mg ml À1 of each of aprotinin, pepstatin and leupeptin) and homogenised using a polytron and spun at 12 000 r.p.m. for 10 min at 41C. Lysates were separated on 15% SDS -PAGE, transferred to polyvinylidene fluoride membranes, blocked in 10% w/v dry milk, incubated with a mouse monoclonal anti-human VEGF xxx b antibody (2 mg ml À1 , R&D Systems) for 1 h followed by horse radish peroxidase conjugated anti-mouse antibody (1/5000, Pierce Biotechnology) for 1 h. Membranes were developed using supersensitive West Femto Maximum Sensitive Substrate (Pierce Biotechnology). Densitometry analysis of western blots was performed using Image J. VEGF 121 b is detected by immunoblotting using anti-VEGF antibodies (A-20 Santa Cruz or AF-293 R&D Systems) and the commercial VEGF xxx b antibody (A56/1, R&D Systems, cat no. MAB3045). Commercial ELISA for VEGF 165 b (R&D Systems) and panVEGF (Duoset R&D Systems) can pick up VEGF 121 b but panVEGF ELISA underestimates the VEGF 121 b levels (and VEGF 165 b) by approximately 40% (Varey et al, 2008) .
Oxygen-induced retinopathy mouse model
The oxygen-induced retinopathy (OIR) model was performed as described earlier (Smith et al, 1994; Konopatskaya et al, 2006) with minor modifications. Neonatal C57/Bl6 mice and nursing CD1 dams were exposed to 75% oxygen between P7 and P12. Return to room air induced hypoxia in the ischaemic areas. On P13, mice received either VEGF 121 b (1 or 10 ng) or Hank's buffered solution in 1 ml intraocular injections using a Nanofil syringe fitted with a 35 gauge needle (WPI, Sarasota, FL, USA) into the left eye under isoflurane anaesthesia. On P17, both eyes were dissected, fixed in 4% paraformaldehyde for 4 h at 41C and retinas were dissected. Retinas were permeabilised in PBS containing 0.5% Triton X-100 and 1% bovine serum albumin, stained with 20 mg ml À1 biotinylated isolectin B4 (Sigma Aldrich) in PBS pH 6.8, 1% Triton-X100, 0.1 mM CaCl 2 , 0.1 mM MgCl 2, followed by 20 mg ml À1 ALEXA 488-streptavidin (Molecular Probes, Eugene, OR, USA) and flat mounted in Vectashield (Vector Laboratories). Quantification of neovascular and ischaemic areas were performed in a blinded fashion using Photoshop CS3 along with Image J and expressed as percentage of total retinal area ( ¼ normal þ ischaemic þ neovascular).
Statistical analysis
Statistical analysis was performed using GraphPad Prism software (version 4.0cx). Data are given as means ± s.e.m. or means ± 95 % confidence interval when stated. One-way ANOVA was used to compare migration, cytoprotection, tumour growth and retinal vascularisation. T-test was used to compare tumour growth, apoptosis and microvascular density and paired t-test used for retinal areas.
RESULTS
Expression of VEGF 121 b in human colon tissue and its reduction in colon carcinoma
Earlier, we reported a shift in expression of VEGF xxx b isoforms in human malignant melanoma (Pritchard-Jones et al, 2007) , prostate (Woolard et al, 2004; Rennel et al, 2008a) and colon carcinoma (Varey et al, 2008) leading to less anti-angiogenic VEGF xxx b splice isoforms in cancer tissue. The ELISA used to quantify the levels of VEGF xxx b isoforms does not distinguish between the individual members of the VEGF xxx b isoform family. Earlier RT -PCR used to detect VEGF xxx b isoforms (using exon 7 and 3 0 UTR primers) did not detect VEGF 121 b (see Figure 2A) as the forward primer was in exon 7 (spliced out in VEGF 121 b and VEGF 121 ). To identify VEGF 121 b, mRNA primers were used that spanned the exon 5/exon 8b boundary. These primers detected VEGF 121 b but not VEGF 165 b or VEGF 165 (see Figure 2B ). VEGF 121 b was detected in normal tissue such as aorta, spleen, placenta and some normal and tumour colon tissue (see Figure 2B ), which also expressed VEGF 165 and VEGF 165 b (see Figure 2A ) and retina and vitreous ( Figure 2C ). Presence of VEGF 121 b was confirmed by sequencing of PCR products.
Measurement of VEGF levels in an earlier study on human colon carcinoma showed that the angiogenic VEGF isoforms were upregulated compared with matched colon tissue whereas the levels of anti-angiogenic VEGF xxx b isoforms remained unchanged. Western blot on that tissue showed two bands consistent with expression of VEGF 121 b and VEGF 165 b (Varey et al, 2008) . Quantification of the western blot analysis of paired human colon tissues from tumour and adjacent normal colon tissue indicates a downregulation of VEGF 121 b in tumour tissue compared to VEGF 165 b (see Figure 2D , Po0.01 paired t-test, n ¼ 14 pairs).
VEGF 121 b is secreted, inhibits migration and reduces apoptosis in endothelial cells
To determine whether VEGF 121 b can be secreted by colon cells, VEGF 121 b recombinant cDNA was transfected into colon carcinoma cells. Western blotting of the lysate and the media showed that VEGF 121 b was found pre-dominantly in the media, indicating that it is freely secreted (see Figure 3A) , in contrast to cells that were not transfected with the VEGF 121 b plasmid, in which no VEGF 121 b was seen in the media or the lysate. VEGF 121 b binding to VEGFR-1 was analysed by incubating increasing concentrations of radiolabelled VEGF 121 b with immobilised VEGFR-1 (see Figure 3B) . The saturation-binding kinetics of VEGF 121 b (see Figure 3B , log 10 EC 50 ¼ À9.9 ± 0.04) was similar to that for VEGF 165 b measured at the same time (EC 50 ¼ À9.65 ± 0.04, Figure 3C ).
We have shown earlier that VEGF 165 b conditioned media (Bates et al, 2002; Rennel et al, 2008a) or recombinant human VEGF 165 b (Woolard et al, 2004; Rennel et al, 2008b) inhibits VEGF 165 -induced migration of endothelial cells. Migration of HUVEC was inhibited by the addition of VEGF 121 b either when stimulated with VEGF 165 (see Figure 3D , VEGF 165 vs any treatment Po0.05) or VEGF 121 (see Figure 3E , VEGF 121 vs any treatment Po0.05). The level of inhibition was similar to that observed with VEGF 165 b (see Figure 3D ) and no additional significant reduction in migration was observed with the combination of VEGF 121 b and VEGF 165 b (see Figure 3D ). Addition of up to 100 mM peptide of the last six amino acids had no effect on VEGF 165 -induced HUVEC migration (data not shown) indicating that the 3D structure and or the full length of the VEGF xxx b protein is needed for inhibition.
VEGF 165 is known to protect endothelial cells from apoptosis and incubation of HUVECs with recombinant VEGF 121 b was equally cytoprotective (see Figure 3F , no addition vs any treatment Po0.01). This resulted in a small increase in cell number induced by treatment with VEGF 121 b (see Figure 3G) . To determine the mechanism of this cytoprotective effect of VEGF 121 b, HUVECs were treated with inhibitors of receptor tyrosine kinases and signalling kinases (see Figure 3H) . Inhibition of VEGFR-1 and VEGFR-2 by 100 nM PTK787 resulted in an inhibition of the cytoprotective effect of VEGF 121 b, as did incubation with the VEGFR-2-specific antagonist ZM323881 (10 nM). The cytoprotective effect was blocked by inhibitors of PI3Kinase (LY294002) and MEK1/2 (PD98059), but not by inhibitors of p38 MAPK (SB203580, see Figure 3H ).
Over-expression of VEGF 121 b reduces tumour growth through a direct effect on endothelial cells
We have shown earlier that over-expression of VEGF 165 b reduces tumour growth in five different tumour types (Woolard et al, 2004; Varey et al, 2008; Rennel et al, 2008a) , but VEGF 165 b does not directly affect proliferation or apoptosis of LS174t cells (Varey et al, 2008) . To verify whether VEGF 121 b could inhibit tumour growth as well, LS174t colon carcinoma tumour cells were transfected with plasmid containing VEGF 121 b or cloning vector alone (control). Expression levels were confirmed by immunoblot on lysate and conditioned media showing that VEGF 121 b was secreted and found in the media (see Figure 3A ). Cells were injected into the back of nude mice and tumour growth was monitored over time. VEGF 121 b reduced tumour growth compared with empty vector (290 ± 66 mm 3 vs 925 ± 268 mm 3 after 14 days, Po0.05, unpaired t-test Welch correction, see Figure 4A ). VEGF 121 b tumours were smaller and excised tumours were less haemorrhagic than those with empty vector (see Figure 4A inserted images). Immunohistochemical staining was performed to visualise blood vessel distribution (see Figure 4B for representative VEGFR-2 staining). Analysis of the vessel density in 10 random fields in each tumour showed a decreased number of vessels in VEGF 121 b tumours (control vs VEGF 121 b, 3.5±0.6 vs 1.7 ± 0.1, Po0.05 unpaired t-test n ¼ 6 tumours per treatment 10 fields analysed per tumour, Figure 4B ). VEGFR-2 staining of tumour sections showed expression of VEGFR-2 in the tumour vessels and not in the general tumour mass (see Figure 4B inserted images) indicating an effect of VEGF 121 b on the endothelium rather than an anti-proliferative effect on the tumour cells. Earlier analysis has shown absence of VEGFR-1 and VEGFR-2 expression in LS174t cells (Rennel et al, 2008b) . To determine whether VEGF 121 b expression induced apoptosis in the tumour cells, tumours were stained for cleaved caspase 3. There was no change in caspase staining in control vs VEGF 121 b-expressing tumours (see Figure 4C) .
Transfected LS174t colon cells were analysed by flow cytometry and VEGF 121 b had no effect on proliferation (see Figure 4D control vs VEGF 121 b, S/G 2 -M 21±2.3 vs 27±4.4, P ¼ 0.36 unpaired t-test). In addition, addition of recombinant VEGF 121 b had no effect on tumour cell number (see Figure 4F ). These data indicate that VEGF 121 b reduced tumour growth by reducing the tumour-driven angiogenesis, rather than a direct effect on the tumour cells themselves. 
Biodistribution of intravenous VEGF 121 b
The results above indicate that VEGF 121 b could be a potential therapeutic agent in angiogenic diseases, if the uptake into neovascular tissues was sufficient. To determine how intravenously (i.v.) injected recombinant VEGF 121 b is distributed in vivo, tomography (NanoSPECT/CT). Radiolabelled VEGF 121 b was distributed quickly through the mouse and images acquired at 40 min post injection (p.i.) showed accumulation in organs of metabolism and secretion. Thereafter, the overall signal gradually declined because of excretion/degradation of the radiolabelled protein. Figure 5A shows whole body images at different time p.i. Uptake of radioactivity can be seen in the tumour as well as abdominal tissues such as stomach and kidney. Coronal and sagittal sections also visualised uptake in the tumour at 2 h p.i. (see Figure 5E -F). Biodistribution of tissue and tumour indicated that approximately 2.5% of the total 125 I is found in the tumour at 2 h and stays at a similar level for up to 24 h (see Figure 5G ). Intestine and liver showed high uptake with a maximum at 4 h. No obvious adverse haemodynamic effects were seen in the animals.
VEGF 121 b rescues retinal vasculature by reducing neovascularisation and ischaemia
We have shown earlier that the anti-angiogenic VEGF 165 b can inhibit retinal neovascularisation in an OIR mouse model when administered as a single intraocular injection (Konopatskaya et al, 2006) . In this model retinal vaso-obliteration occurs in the central retina when pups are exposed to high oxygen (from P7 to P12) and when returned to room air the relative hypoxia induces neovascularisation with a peak reached at P17. Retinas were flat mounted and stained with isolectin to visualise vessels with neovascularisation occurring at the edge of the central ischaemic area (see Figure 6A ). Blind quantification of the injected and uninjected contralateral retina, showed reduced neovascularisation after 1 or 10 ng VEGF 121 b (see Figure 6B- Figure 6D -E, control injection vs 10 ng VEGF 121 b Po0.05 for ischaemic and normal vessel growth). The overall result was an increase in the proportion of normal vasculature in these retinae (see Figure 6E ). Injection of control solution had no effect compared with contralateral eye (see Figure 6B uninjected control vs control injected eye, P40.05, paired t-test). 
DISCUSSION
The existence of a second family of VEGF isoforms with overtly different properties from that of the conventional VEGF species required a radical re-evaluation of VEGF biology, not only academically -thousands of manuscripts have attempted to quantify 'VEGF' in body fluids or tissues using primers, probes or antibodies that would not distinguish these contrasting families; but also in terms of the pathogenesis of disease and the potential clinical importance of VEGF xxx /VEGF xxx b balance, because these families derive from the same gene. VEGF 165 b is widely expressed (Bates et al, 2002 Cui et al, 2004; Perrin et al, 2005; Pritchard-Jones et al, 2007; Varey et al, 2008) and may form the pre-dominant isoform in many tissues (Perrin et al, 2005; Varey et al, 2008) . The physiological role of these isoforms is only just now being elucidated in normal tissues, and it seems that they act as a brake on excess angiogenesis during conditions of controlled growth or VEGF xxx expression. Examples include development of the ovary, where the VEGF xxx b levels are maintained to prevent angiogenesis into the developing germ bud and so prevent formation of a testicular artery (VEGF xxx b antibodies are angiogenic in this model, Artac et al, in press) , in the virgin mammary fat pad, where VEGF xxx levels are prevented from inducing angiogenesis until lacteal formation, when VEGF xxx b levels fall (and prevention of this fall results in reduced milk production) , and in the eye where a relative drop in VEGF xxx b levels is accompanied with angiogenesis in the retina in diabetes (Perrin et al, 2005) . Increased VEGF xxx b levels also seem to be required for normal pregnancy, as a failure to upregulate VEGF xxx b in first trimester pregnancies is associated with subsequent maternal -fetal pathology (Bills et al, 2009) .
The development of an angiogenic milieu within a stable and non-angiogenic tissue, may depend to some degree on changes in gene (over) transcription or suppression but also on changes in mRNA splicing control. The control of splicing between the two VEGF isoform families has begun to be elucidated, and it has been shown that multiple stimulatory signals can differentially affect the choice of splice site in the terminal exon, including hypoxia (Varey et al, 2008) , IGF, TNF and PDGF (Nowak et al, 2008) , which all favour proximal splice site selection in exon 8, and hence angiogenic isoforms, and the latter three growth factors suppress distal splicing, whereas hypoxia seems not to affect it. TGF-b, on the other hand, seems to favour distally spliced isoforms (Nowak et al, 2008) . This seems to be through mechanisms involving splice factors such as ASF/SF2 and SRp55. Additionally, alteration of splicing has been seen in human and animal models of disease including in Denys Drash Syndrome (Schumacher et al, 2007) , kidney, prostate and colon cancer (Bates et al, 2002; Woolard et al, 2004; Varey et al, 2008; Rennel et al, 2008a) , malignant melanoma (Pritchard-Jones et al, 2007) where the PSS is favoured and animal models of glaucoma where the DSS is favoured (Ergorul et al, 2008) . However, there is very little known about regulation of splice site choice in the terminal exon from the exon 5 splice donor site, but the earlier studies on hypoxia indicate that this is unlikely to be a regulatory factor for VEGF 121 b.
The most studied VEGF xxx b family member -VEGF 165 b -has been clearly shown not to be angiogenic. Other researchers have shown that the six amino acids of exon 8b are required for the antiangiogenic activity of VEGF 165 b because artificially generated VEGF 159 lacking both exons 8a and b, which is not angiogenic (Cebe Suarez et al, 2006) . Exon 8a seems to be required for heparin and neuropilin-1 binding and full activation of the VEGFR-1 and -2, as it is likely to interfere with the correct folding and 3D structure of the protein, resulting in differential activation of VEGFR-2 tyrosine phosphorylation, and hence downstream signalling (Cebe Suarez et al, 2006; Cebe-Suarez et al, 2008; Kawamura et al, 2008) . Here, we present for the first time new data suggesting that the presence of exon 8b in a different VEGF xxx b family member endows it with similar properties to VEGF 165 b: VEGF 121 b inhibits experimental endothelial cell migration in vitro and new vessel formation in vivo in tumour and non-tumour-related angiogenesis. The VEGF xxx b family members seem to share similar properties.
We have shown that VEGF 121 b has similar bio-distribution after i.v. injection to VEGF 165 b and a similar proportion of injected bolus reaching a single implanted tumour -with around 2% for VEGF 121 b and 6% for VEGF 165 b (Rennel et al, 2008b) . Furthermore, we have shown in this study and in our earlier work (Woolard et al, 2004) that these two VEGF xxx b family members bind the conventional tyrosine kinase VEGF receptors. VEGF 165 b does not bind neuropilin-1 (Kawamura et al, 2008) , and there is evidence that VEGF 121 also binds neuropilin poorly, suggesting that VEGF 121 b would not bind it either. von Wronski et al (2007) have highlighted the likelihood that neuropilin-1 binds the residues coded for by exon 8a and replacement by 8b results in VEGF isoforms that do not seem to show neuropilin-1 binding (Cebe Suarez et al, 2006) .
Although we have shown that VEGF 165 b and VEGF 121 b bind to the conventional VEGF receptors, further work will be required to investigate the mechanistic differences between VEGF 121 b and its corresponding isoform VEGF 121 . Studies into the mechanistic contrast between VEGF 165 b and VEGF 165 are more advanced with increasing evidence now emerging that VEGF 165 b, although binding to VEGFR-2 with equal affinity as VEGF 165 , is not simply a classical competitive inhibitor. VEGF 165 b does stimulate the phosphorylation of VEGFR-2 but qualitatively in a unique way. Although VEGF 165 b does lead to the phosphorylation of tyrosine residues of the VEGF receptor, tryptic phosphopeptide mapping and the use of phosphosite-specific antibodies have shown that VEGF 165 b is considerably poorer than VEGF 165 in inducing phosphorylation of the angiogenic positive regulatory site Y1052 (Y1054 in human sequence) in VEGFR-2 (Kawamura et al, 2008) . This study also confirmed that the ability of different VEGF isoforms to induce angiogenesis correlated with their abilities to bind the VEGF co-receptor neuropilin-1 (Kawamura et al, 2008) . Whether or not VEGF 121 b activates VEGFR-2 in a similar way is yet to be investigated, as are the potential effects of simultaneous VEGF 121 b and VEGF 165 b administration of receptor activity, angiogenesis or tumour growth.
Another significant finding here is that VEGF 121 b seems to act as a survival factor for human endothelial cells. This activity seems to be VEGFR dependent, and uses classical survival pathways such as the PI3 kinase and MEK/ERK pathways. This provides a potential explanation for the surprising finding that the ischaemic region in the retinal neovascular preparations was reduced by VEGF 121 b administration. This is of particular interest as it suggests a vascular normalisation in the retina, leading to the possibility that VEGF 121 b may be of use in ischaemic retinal diseases associated with angiogenesis such as diabetic retinopathy.
In summary, we provide new information about the existence, expression and activity of a second member of the anti-angiogenic VEGF xxx b family. Our data confirm that VEGF 121 b has similar inhibitory properties on the process of in vivo angiogenesis and the components of angiogenesis in vitro as does VEGF 165 b, supporting the notion that the replacement of the terminal six amino acids with those coded for by exon 8b is of crucial importance in converting the dominant pro-angiogenic growth factor into a positively anti-angiogenic molecule that may have broad therapeutic potential. Further studies will be required to elucidate its mechanism of action of VEGF 121 b and its potential clinical value along with its other family member VEGF 165 b.
